1 completed, 1 terminated. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Terminated 1 |
Follow COVID-19 Severe Pneumonia: new trials by email Literature Review of COVID-19 Severe Pneumonia trials Research Report on COVID-19 Severe Pneumonia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia Ravulizumab, BSC - COVID-19 Severe Pneumonia, Acute Lung Injury | Phase 3 | Terminated | Alexion Pharmaceuticals, Inc. | 202 | 2020-05-10 | 2022-05-24 |
| Lipid Metabolism in COVID-19 Severe Pneumonia Compared With Severe Pneumonia Caused by Other Pathogen biological assays in particular on the lipid metabolism - COVID-19 Severe Pneumonia, Severe Pneumonia Due to Other Pathogene | Completed | Centre Hospitalier Universitaire Dijon | 62 | 2020-04-07 | 2026-02-02 |
Acute Lung Injury (1) · COVID-19 (1) · Pneumonia (1) · Pneumonia, Viral (1) · Respiratory Distress Syndrome (1) · Severe Acute Respiratory Syndrome (1)
Coronaviridae Infections (1) · Coronavirus Infections (1) · Infections (1) · Lung Diseases (1) · Lung Injury (1) · Nidovirales Infections (1) · RNA Virus Infections (1) · Respiration Disorders (1) · Respiratory Tract Diseases (1) · Respiratory Tract Infections (1) · Virus Diseases (1)
Biological Assay (1) · ravulizumab (1)
Alexion Pharmaceuticals, Inc. (1) · Centre Hospitalier Universitaire Dijon (1)
France (2) · Japan (1) · Spain (1) · United Kingdom (1) · United States (1)
PMID 32554923, PMID 32660611, PMID 33826106, PMID 34031519, PMID 34473343, PMID 36958364